UCLA researchers use “rapid autopsies” to identify lethal molecular alterations in relapsed metastatic melanoma

UCLA study: AI model can help predict survival outcomes for patients with cancer

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have developed an artificial intelligence model based on epigenetic factors that is able to predict patient outcomes successfully across multiple cancer types.

November 17, 2023

Vol.49 No.43

Clinical Roundup

UCLA scientists engineer potent immune cells for “off-the-shelf” cancer immunotherapy

UCLA scientists developed a novel method to engineer more powerful immune cells that can potentially be used for “off-the-shelf” cell therapy to treat challenging cancers.

November 10, 2023

Vol.49 No.42

Clinical Roundup

SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50%

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant Keytruda (pembrolizumab).

October 27, 2023

Vol.49 No.40

Drugs & Targets

FDA approves nivolumab for adjuvant treatment of stage 2B/C melanoma

FDA approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage 2B/C melanoma in patients 12 years and older.

October 20, 2023

Vol.49 No.39

In Brief

UCLA’s Mina Sedrak receives $3.4M from NIH to study accelerated aging in breast cancer survivors

Mina Sedrak, associate professor of medicine at the David Geffen School of Medicine at UCLA and director of the Cancer and Aging Program at the UCLA Health Jonsson Comprehensive Cancer Center, received a five-year, $3.4 million grant from NIH to examine how exercise and certain drugs may be able to slow chemotherapy-related accelerated aging seen in breast cancer survivors.

September 29, 2023

Vol.49 No.36

In Brief

UCLA researchers awarded $2.5M from DoD to develop brain cancer treatment

A multidisciplinary team of investigators from the UCLA Jonsson Comprehensive Cancer Center was awarded a $2.5 million Translational Team Science Award from the Department of Defense to develop a tailored treatment for glioblastoma, a deadly brain tumor with limited treatment options.

September 15, 2023

Vol.49 No.34

UCLA researchers use “rapid autopsies” to identify lethal molecular alterations in relapsed metastatic melanoma

YOU MAY BE INTERESTED IN

UCLA study: AI model can help predict survival outcomes for patients with cancer

UCLA scientists engineer potent immune cells for “off-the-shelf” cancer immunotherapy

SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50%

FDA approves nivolumab for adjuvant treatment of stage 2B/C melanoma

UCLA’s Mina Sedrak receives $3.4M from NIH to study accelerated aging in breast cancer survivors

UCLA researchers awarded $2.5M from DoD to develop brain cancer treatment

Renew today!

Subscriber content

Login